Fusi-Rubiano W, et al. - In a 'real world' setting, experts assessed the visual function and structural improvements in pseudophakic eyes with diabetic macular oedema (DMO) treated with the 0.19mg Fluocinolone Acetonide (FAc) intravitreal implant (Iluvien). An additional evidence was provided by the evaluation of the 0.19mg FAc implant, that it was efficacious and safe in the treatment of patients with DMO, and could provide sustained benefit for cases with previously refractory disease.